The Role of Long-Acting Antipsychotics in Patients Suffering a Schizophrenia and Comorbid Drug Use The Case of Paliperidone Palmitate
International Journal of Dual Diagnosis
Volume 2, Issue 1, March 2017, Pages: 8-12
Received: Feb. 28, 2017; Accepted: Mar. 4, 2017; Published: Mar. 21, 2017
Views 1995      Downloads 61
Authors
Núñez Domínguez L. A., Medical Center, Pamplona, Navarra, Spain
Barrado Los Arcos L., Mental Health Net, Pamplona, Navarra, Spain
Saiz García H., Mental Health Center, Pamplona, Navarra, Spain
López Olmo N., Psychiatric Hospital, Vitoria, País Vasco, Spain
Arbeo Ruiz O., Centro de Día Zuría, Pamplona, Navarra, Spain
García Nicolás M., Mental Health Center, Tudela, Navarra, Spain
Article Tools
Follow on us
Abstract
The psychopharmacological treatment of psychotic dual disorders is a real challenge for the clinicians, due to the low level of adherence to the treatment in many cases. For this reason, in some recent guides (Cochrane, Nice) it had been proposed the use of Long-term antipsychotic treatment (LAI-APS) as a way to improve the adherence and increase the efficacy of the treatment. Paliperidone Palmitate is one the most recent LAI-APS, with very good results in the treatment of psychotic disorder, with low number of drop-outs due to the good tolerability to these effects. The authors carry-out a preliminary study comparing the tolerability and efficacy of this LAI-APS in two samples of schizophrenic patients, one of them with comorbid drug use. Our results shows that the treatment permits in both groups the decrease of dosage and/or number of concomitant oral antipsychotic treatment, decrease the number of psychiatric admissions and the use of drug, with no drop-out during a period of one years, comparing with the previous year. We conclude that Paliperidone Palmitate could be a useful treatment in the group of patients suffering psychotic disorder with comorbid drug use.
Keywords
Dual Disorders, Schizophrenia, Paliperidone Palmitate
To cite this article
Núñez Domínguez L. A., Barrado Los Arcos L., Saiz García H., López Olmo N., Arbeo Ruiz O., García Nicolás M., The Role of Long-Acting Antipsychotics in Patients Suffering a Schizophrenia and Comorbid Drug Use The Case of Paliperidone Palmitate, International Journal of Dual Diagnosis. Vol. 2, No. 1, 2017, pp. 8-12. doi: 10.11648/j.ijdd.20170201.12
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Ameller A, Gorwood P (2015) Attributable risk of co-morbid substance use disorder in poor observance to pharmacological treatment and the occurrence of relapse in schizophrenia. Encephale.; 41 (2): 174-83.
[2]
Carrà G, Crocamo C, Borrelli P, Popa I, Ornaghi A, Montomoli C, Clerici M (2015) Correlates of dependence and treatment for substance use among people with comorbid severe mental and substance use disorders: findings from the "Psychiatric and Addictive Dual Disorder in Italy (PADDI)" Study. Compr Psychiatry, 58: 152-9
[3]
Castillo EG, Stroup TS (2015) Effectiveness of long-acting injectable antipsychotics: a clinical perspective. Evid Based Mental Health; 18: 36-39
[4]
Clarke N, Mun EY, Kelly S, White HR, Lynch K. (2013) Treatment outcomes of a combined cognitive behavior therapy and pharmacotherapy for a sample of women with and without substance abuse histories on an acute psychiatric unit: do therapeutic alliance and motivation matter? Am J Addict.; 22 (6): 566-73.
[5]
Chambers RA, Krystal JH, Self DW. (2001) A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry., 15; 50 (2): 71-83.
[6]
Dixon L (1999) Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 35, Supplement 1, pp S93–S100.
[7]
Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC.(2005) Cannabis use predicts future psychotic symptoms, and vice versa. Addiction; 100 (5): 612-8.
[8]
Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS; HGDH Research Group. (2004) First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res., 66 (2-3): 125-35.
[9]
Green AI, Noordsy DL, Brunette MF, O'Keefe C (2008) Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat., 34 (1): 61-71.
[10]
Guía Cochrane. McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, Kyprianou Cannabis for schizophrenia (oct 2014).
[11]
Haddock G, Eisner E, Davies G, Coupe N, Barrowclough C. (2013) Psychotic symptoms, self-harm and violence in individuals with schizophrenia and substance misuse problems. Schizophr Res; 151 (1-3): 215-20.
[12]
Hasin DS, Grant BF. (2015) The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol.; 50 (11): 1609-40.
[13]
Khantzian EJ. (1985) The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 142 (11): 1259-64.
[14]
Koola MM, Wehring HJ, Kelly DL (2012) The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use. J Dual Diagn.; 8 (1): 50-61.
[15]
Large M, Mullin K, Gupta P, Harris A, Nielssen O (2014) Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. Aust N Z J Psychiatry.; 48 (5): 418-32.
[16]
Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P (2014) Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychol Med; 44 (12): 2513-21.
[17]
Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K. (2004) Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res., 67 (2-3): 157-66.
[18]
Marquez-Arrico JE, Benaiges I, Adan A (2015) Strategies to cope with treatment in substance use disorder male patients with and without schizophrenia. Psychiatry Research, Published Online: June 03, 2015, In Press Accepted Manuscript.
[19]
NICE guidelines [CG120] Psychosis with coexisting substance misuse: Assessment and management in adults and young people Published date: March 2011.
[20]
Núñez Domínguez LA, García Nicolás MC, Arbeo Ruiz, O (2014) Paliperidone Palmitate in dual pathology. A retrospective study. Adicciones Intepsiquis 2014. Congreso Virtual de Psiquiatría.
[21]
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA.; 264 (19): 2511-8.
[22]
Ross S, Peselow E (2012) Co-occurring psychotic and addictive disorders: neurobiology and diagnosis. Clin Neuropharmacol; 35 (5): 235-43.
[23]
Rubio G, Martínez I, Ponce G, Jiménez-Arriero MA, López-Muñoz F, Alamo C. (2006) Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry.; 51 (8): 531-9.
[24]
Samaha AN (2014) Can antipsychotic treatment contribute to drug addiction in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatr, 3; 52: 9-16.
[25]
Sepede G, Lorusso M, Spano MC, Di Iorio G, Martinotti G, et al. (2014) Substance Use in Schizophrenia: Efficacy of Atypical Antipsychotics. J Schizophr Res, 1 (1): 1-12.
[26]
Talamo A, Centorrino F, Tondo L, Dimitri A, Hennen J, Baldessarini RJ.(2006) Comorbid substance-use in schizophrenia: relation to positive and negative symptoms. Schizophr Res., 86 (1-3): 251-5.
[27]
Tang L, Zhang Q, Li j, Gu T, Ruan Y, Tang Y, Zhang S, Hu L, Zhao L et al., (2015) A NR3C2 haplotype increases the risk of alcoholism in schizophrenic patients in Han Chinese population. Psychiatry Research, art in press, http://dx.doi.org/10.1016/j.psychres.2015.05.027
[28]
TREATMENT GUIDELINES) World Federation of Societies of Biological Psychiatry (WFSBP). Guidelines for Biological Treatment of Schizophrenia.. Part 3: Update 2015. Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. The World Journal of Biological Psychiatry; 16: 142-170.
[29]
van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H.(2002) Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol, 15; 156 (4): 319-27.
[30]
Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS.(2004) Cannabis use and age at onset of schizophrenia. Am J Psychiatry.; 161 (3): 501-6.
[31]
Wisdom JP (2011) Substance Use Disorder Among People with First-Episode Psychosis: A systematic Review of Course and Treatment. Psychiatr Serv; 62 (9) 1007-1012.
[32]
Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. (2008) Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186